乌干达HIV-1 A1和D亚型及重组株天然多态性与来那卡帕韦耐药相关
研究分析了乌干达西南部546例未接受抗逆转录病毒治疗的HIV-1感染者血浆样本中Gag p24(衣壳)序列,未发现主要来那卡帕韦耐药相关突变,次要突变见于1.6%的参与者,以T107A最常见。系统发育分析提示携带T107A的个体在进化树上独立分布,T107A可能源自多次不同的碱基替换事件。作者认为乌干达天然存在的来那卡帕韦耐药突变流行率低,支持来那卡帕韦在该地区的潜在疗效。
要点
- 546例来那卡帕韦初治者中未发现主要来那卡帕韦耐药相关突变。
- 次要突变见于1.6%的参与者,以T107A最常见。
- 一名参与者ART启动后T107A持续至少3年。
核心结论
- 乌干达天然存在的来那卡帕韦耐药突变流行率低,支持来那卡帕韦在该地区的潜在疗效。
研究设计与样本
- 利用乌干达未接受ART的成人血浆样本,分析HIV-1 Gag p24(衣壳)序列中的来那卡帕韦耐药突变,共546例来那卡帕韦初治参与者。
主要发现
- 546例来那卡帕韦初治参与者中未发现主要来那卡帕韦耐药相关突变。
- 次要突变见于1.6%的参与者,以T107A最常见。
- 纵向数据显示一名参与者在ART启动后T107A持续至少3年。
- 系统发育分析显示携带T107A的个体在进化树上分布于不同位置,提示T107A可能源自多次不同的碱基替换事件。
- Shannon熵分析显示部分衣壳位点变异度高,但均未与已知来那卡帕韦耐药位点重叠。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lenacapavir, a novel HIV-1 capsid inhibitor, shows promise for treating MDR HIV-1, as well as for pre-exposure prophylaxis (PrEP) in prevention of HIV infection. Its unique mechanism and lack of cross-resistance with other antiretroviral classes make lenacapavir a significant addition to HIV therapy. The clinical trials CALIBRATE and CAPELLA have demonstrated high viral suppression rates in both ART-naive individuals and individuals with MDR HIV-1. Lenacapavir-associated resistance mutations, such as M66I and Q67H, rarely seen as natural polymorphisms in lenacapavir-naive populations, are predominantly studied in subtype B HIV-1. OBJECTIVES: Our study aimed to investigate the prevalence of lenacapavir resistance-associated mutations in HIV-1 subtypes A1 and D in a cohort of individuals living with HIV-1 from southwestern Uganda. METHODS: Utilizing plasma samples from ART-naive adults living in Uganda, HIV-1 Gag p24 (capsid) sequences were analysed for lenacapavir resistance mutations. RESULTS: Among 546 lenacapavir-naive participants, no major lenacapavir resistance-associated mutations were found. Minor mutations were present in 1.6% of participants, with T107A being the most common. Longitudinal data indicated the persistence of T107A for at least 3 years post-ART initiation in one participant. Phylogenetic analysis indicated individuals carrying T107A were found independently in distinct locations within the tree, suggesting that T107A might have arisen from multiple distinct base substitution events. Shannon entropy analysis showed high variability in certain capsid sites, but none overlapped with known lenacapavir resistance sites. CONCLUSIONS: These findings suggest a low prevalence of naturally occurring lenacapavir resistance mutations in Uganda, supporting lenacapavir's potential efficacy in this region.
引用
- Omoding D, Musinguzi N, Boum Y, et al. Subtypes A1 and D, and recombinant HIV-1 natural polymorphisms associated with lenacapavir drug resistance in Uganda. J Antimicrob Chemother. 2025. PMID: 39881519. doi:10.1093/jac/dkaf018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。